Anti Cd 20 Ocrevus denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Ocrevus as Duplicate Therapy

Blue Cross Blue Shield's duplicate-therapy denial for Ocrevus (ocrelizumab) means BCBS has identified another disease-modifying therapy on your active medication record — typically another anti-CD20 agent, a natalizumab infusion, or a high-efficacy oral DMT — and has determined the two therapies overlap in clinical purpose. This often happens during a planned therapy transition when the prescriber has written orders for Ocrevus before the prior agent has been formally closed out in BCBS's system.

Because BCBS plan designs vary considerably by region and employer contract, you will need to identify whether your plan is governed by ERISA (employer-sponsored self-funded plan), a fully-insured state-regulated plan, or a federal employee plan (FEHB) — the appeal pathway differs, but the substantive arguments are the same.

## Federal Appeal Rights

• Internal appeal: ERISA §503 guarantees a full-and-fair review for employer plans. ACA rules apply to individual and small-group plans. State insurance law governs fully-insured plans. The deadline is on your denial letter — act promptly.
• External review: Under ACA §2719, if the internal appeal fails, an Independent Review Organization reviews the denial independently of BCBS. The filing window is approximately four months from the final internal denial.
• Expedited review: Available when your neurologist certifies that standard timelines would pose a serious health risk — for example, a gap in MS therapy during an active relapse period.

## What to Gather

1. Therapy transition documentation — a complete medication reconciliation showing which prior DMT is being stopped, the planned discontinuation or washout timeline, and that Ocrevus is the replacement — not a concurrent addition. 2. Prescriber letter of medical necessity — your neurologist must explicitly state that this is a sequential therapy switch and describe the clinical rationale for the transition: why the prior agent is being stopped and why Ocrevus is the appropriate successor. 3. Diagnosis and disease-activity records — current neurologist notes, MRI reports, and relapse or progression history supporting the need for a high-efficacy DMT transition. 4. BCBS medical policy for ocrelizumab — locate the applicable BCBS plan's clinical coverage criteria (policies vary by BCBS entity). Download it and map each criterion.

## Criteria-Mapping Structure

| BCBS Policy Requirement | Chart Documentation | |---|---| | Confirmed MS diagnosis with subtype | Neurology note + MRI | | Only one high-efficacy DMT active at a time | Medication reconciliation with discontinuation date | | Transition is sequential, not concurrent | Prescriber letter stating switch intent | | Prior agent discontinued or tapering | Prescribing records; pharmacy records |

The resolution to this denial is almost entirely administrative: demonstrate, with dates, that one therapy is ending and the other is beginning. A clear medication timeline — not a clinical argument — is what wins this appeal.